Antigen discovery and Immuno Biology- Enhancing our knowledge of the Human Leukocyte Antigen (HLA) class I/II processes of antigen processing/presentation by mass spectrometry-based proteomics and immuopeptidomics from the perspectives of the immune system and diseased cells is the primary goal of the Antigen Discovery and Immuno Biology Group. Those learnings will make it possible to improve clinical products, provide new strategies for finding targetable HLA-bound antigens and to decipher what/how T cell recognize.
Additionally, the team will lead the way in analytical advancements such as biochemical workflows including automatization, liquid chromatography (LC), ion mobility (IM), mass spectrometry (MS), alternative fragmentations, and bioinformatics, which will facilitate the identification of new biological mechanisms and targetable antigens.
Our lab is part of the Biomolecular Mass Spectrometry and Proteomics group embedded in the Utrecht Institute for Pharmaceutical Sciences (UIPS), Oncode Accelerator (OA) and Princess Maxima Centre (PMC).